机译:The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials
Dept Biomed Sci,Humanitas Univ;
Med Oncol & Hematol Unit,IRCCS Humanitas Res Hosp;
CTLA-4; durvalumab; HCC; immune checkpoint inhibitors; immunotherapy; ipilimumab; nivolumab; PD-1; PD-L1; tremelimumab; PREEXISTING AUTOIMMUNE-DISEASE; PHASE-III; SYSTEMIC TREATMENT; PD-L1 EXPRESSION; CANCER-PATIENTS; DOUBLE-BLIND; SORAFENIB; NIVOLUMAB; EFFICACY;